Heron Therapeutics (HRTX) EBITDA Margin (2010 - 2026)
Heron Therapeutics (HRTX) reported EBITDA Margin of 23.4% for Q1 2026, down 3014.0% on a YoY basis from 0.8% in Q1 2025, and down 221.9% quarter-over-quarter from 7.27% in Q4 2025.
Heron Therapeutics (HRTX) EBITDA Margin (2010 - 2026) Analysis & Trends
Heron Therapeutics has reported EBITDA Margin for 12 years, with the latest figure at 23.4% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 3014.0% year-over-year to 23.4%; the trailing twelve-month figure through Mar 2026 stood at 20.53% (down 1530.0% YoY), and the FY2025 full-year result was 13.04%, down 363.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 23.4%, down from 7.27% in the prior quarter.
- The five-year high for EBITDA Margin was 8.92% in Q4 2024, with the low at 272.37% in Q1 2022.
- Historically, EBITDA Margin has averaged 68.87% across 5 years, with a median of 31.29% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin jumped 19853 bps — and 2025, when it plunged 3115 bps.
- Heron Therapeutics' EBITDA Margin stood at 66.04% in 2022, then surged by 53 bps to 31.29% in 2023, then soared by 128 bps to 8.92% in 2024, then plunged by 182 bps to 7.27% in 2025, then slumped by 222 bps to 23.4% in 2026.
- The last three EBITDA Margin figures came in at 23.4% (Q1 2026), 7.27% (Q4 2025), and 45.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | -23.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.40% |
| Dec 31, 2025 | -7.27% |
| Sep 30, 2025 | -45.78% |
| Jun 30, 2025 | -6.41% |
| Mar 31, 2025 | 6.74% |
| Dec 31, 2024 | 8.92% |
| Sep 30, 2024 | -14.63% |
| Jun 30, 2024 | -25.64% |
| Mar 31, 2024 | -9.17% |
| Dec 31, 2023 | -31.29% |
| Sep 30, 2023 | -79.54% |
| Jun 30, 2023 | -132.47% |
| Mar 31, 2023 | -110.55% |
| Dec 31, 2022 | -66.04% |
| Sep 30, 2022 | -157.98% |
| Jun 30, 2022 | -203.99% |
| Mar 31, 2022 | -272.37% |
| Dec 31, 2021 | -264.58% |
| Sep 30, 2021 | -225.80% |
| Jun 30, 2021 | -272.22% |